Novo Nordisk ADR [NYSE: NVO] closed the trading session at $128.31. The stocks have a year to date performance of 24.03 percent and weekly performance of -0.26 percent. The stock has been moved at 37.23 percent over the last six months. The stock has performed
Novo Nordisk ADR [NYSE: NVO] slipped around -2.48 points on Wednesday, while shares priced at $126.16 at the close of the session, down -1.93%. Compared to the average trading volume of 5.00M shares, NVO reached a trading volume of 3093407 in the most recent trading
Novo Nordisk ADR [NYSE: NVO] closed the trading session at $124.53. The stocks have a year to date performance of 20.38 percent and weekly performance of -0.32 percent. The stock has been moved at 23.11 percent over the last six months. The stock has performed
Novo Nordisk ADR [NYSE: NVO] gained 0.38% or 0.47 points to close at $125.40 with a heavy trading volume of 2417206 shares. The company report on April 8, 2024 at 9:40 AM that Novo Nordisk A/S – share repurchase programme. Novo Nordisk A/S – Share
Novo Nordisk ADR [NYSE: NVO] stock went on a downward path that fall over -0.85% on Tuesday, amounting to a one-week price decrease of less than -2.01%. The company report on April 2, 2024 at 6:56 AM that Novo Nordisk A/S – share repurchase programme.
Novo Nordisk ADR [NYSE: NVO] slipped around -1.36 points on Wednesday, while shares priced at $128.05 at the close of the session, down -1.05%. The company report on March 25, 2024 at 7:58 AM that Novo Nordisk A/S – share repurchase programme. Bagsværd, Denmark, 25
Novo Nordisk ADR [NYSE: NVO] loss -1.14% or -1.52 points to close at $131.37 with a heavy trading volume of 4373146 shares. The company report on March 18, 2024 at 10:18 AM that Novo Nordisk A/S – share repurchase programme. Bagsværd, Denmark, 18 March 2024
Novo Nordisk ADR [NYSE: NVO] loss -2.10% or -2.85 points to close at $133.07 with a heavy trading volume of 12691017 shares. The company report on March 8, 2024 at 2:57 PM that Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known
Novo Nordisk ADR [NYSE: NVO] closed the trading session at $124.65. The company report on March 5, 2024 at 4:53 AM that Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and
Novo Nordisk ADR [NYSE: NVO] slipped around -1.26 points on Tuesday, while shares priced at $122.23 at the close of the session, down -1.02%. The company report on February 26, 2024 at 6:02 AM that Novo Nordisk A/S – share repurchase programme. Bagsværd, Denmark, 26
© 2024, Powered by Smart TechOne
